Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma

Centro de las artes en la Plaza de la Paj

Correlation between molecular subtype and histological phenotype in pancreatic ductal adenocarcinoma

info:eu-repo/semantics/nonPublishe

Pragmatic subtyping of pancreatic ductal adenocarcinoma with markers and histological features.

info:eu-repo/semantics/nonPublishe

Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications

Background: Different histological and molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different molecular composition and survival statistics, have recently been recognised. Materials and methods: This review describes the currently available studies regarding molecular and histological subtypes in PDAC. Studies from major cohorts such as International Cancer Genome Consortium as well as smaller cohorts are reviewed. We discuss where the described subtypes overlap, where the discrepancies are and which paths forward could be taken regarding diagnosis, ontogeny and therapy. Results: Four molecular subtypes with strong overlap among the different studies can be found, next to a list of mixed findings. Two of the four subtypes (epithelial classical and mesenchymal basal-like) were represented in every study and were often discriminated in other solid tumours as well. These two subtypes differ substantially in prognosis. One biomarker has been discovered, only discriminating these two subtypes, and insights into subtype-specific therapeutic vulnerabilities are scarce. Conclusion: Subtypes can be reproducibly detected in cohorts of PDAC patients and two of them directly relate with prognosis. A consensus on the subtypes is warranted. Further discovery and validation studies are needed to identify strong biomarkers, to comprehend subtype ontogeny and to define strategies for precision medicine.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Comparison of Pathological Responses (PR) Observed on Colorectal Cancer Metastases (CRCM) Resected After Different Preoperative Treatments

Background Irinotecan (IR) or oxaliplatin (OX)-based regimens optionally combined with anti-VEGF or anti-EGFR Target Therapies (TT) are used as preoperative treatment for metastatic colorectal patients before resection of CRCM. Best combination remains unclear. The study purpose was to compare PR observed on resected CRCM after different preoperative treatments. Methods 114 patients engaged for CRCM resection after 2005 were included in this retrospective analysis. PR was evaluated on 296 resected CRCM according to the pathological Tumor Regression Grading scale (TRG), grading PR from complete (TRG1) to absent (TRG5). Mean TRG of resected metastasis was compared based on Kruskall-Wallis and Mann-Whitney tests. Cumulative PFS were calculated by Kaplan-Meir method and compared by log-rank test. Results 92/114 patients were preoperatively treated. Mean TRG after OX without TT was better than mean TRG after IR without TT (p = .044). No difference was observed between mean TRG after chemotherapy alone compared to mean TRG after chemotherapy + anti-VEGF (p = .53) or to mean TRG after chemotherapy + anti-EGFR (p = .39). Subgroup analysis revealed that mean TRG after IR + anti-EGFR was better than mean TRG after OX + anti-EGFR (p = .031), and that mean TRG after OX + anti-VEGF was better than mean TRG after IR + anti-VEGF (p = .001). PFS analysis for the 92 preoperatively treated patients revealed that 13 patients with major PR (TRG ≤ 2), had a significantly improved PFS compared to 79 patients with minor or no PR (TRG > 2) (median PFS= 33.7 vs 22.9 month p= .018)

Molecular test algorithms for breast tumours

In order to advise the Federal Government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests, the Commission of Personalized Medicine (ComPerMed) has applied, for the breast tumours, the same methodology as previously applied for the digestive tumours. Meaning, the different molecular tests, represented in the shape of algorithms, are annotated with test levels — which aim to reflect their relevance based on current available data and to define the reimbursement — and are documented with recent literature, guidelines and a brief technical&nbsp;description.</p